Oxford University claims of developing coronavirus vaccine 'CHADOX1', to be available till September. WHO, ICMR thinks the same

According to lead researcher Professor Sarah Gilbert, their 'ChAdOx1' vaccine can work against the coronavirus called SARS-CoV-2.

ChAdOx1 Vaccine, Coronavirus Vaccine, University of Oxford, All About ChAdOx1, What Is ChAdOx1, Frontrunners Of Coronavirus Vaccine, ICMR, WHO, University of Oxford Develops Vaccine- True Scoop

In the times of pandemic, the entire world is waiting for a vaccine that can destroy the novel coronavirus but no breakthroughs have been achieved yet. However, a little spark of hope has come up when scientists at the University of Oxford last week promised a super-fast vaccine during a virtual press conference, saying the vaccine will be available by September.

According to lead researcher Professor Sarah Gilbert, their 'ChAdOx1' vaccine can work against the coronavirus called SARS-CoV-2.

UK Health Secretary Matt Hancock, during the daily press conference at 10 Downing Street, said the government will provide 20 million pounds to the Oxford research team to help fund their clinical trials, with a further 22.5 million pounds for researchers at Imperial College London, reports The Independent.

The Indian Council of Medical Research (ICMR) on Sunday said that a potential vaccine called ChAdOX1 a" being developed by researchers at the University of Oxford -- is the frontrunner in the race to take on the deadly COVID-19 pandemic which has infected over 2.3 million people globally and claimed over 160,000 lives

Three More Frontrunners For Vaccine of COVID-19:

Also Read: Canada woman survives close-range gunshot to chest due to fake breasts

According to the WHO draft, from a total of 70 candidate vaccines in the race, three leading vaccines are in the human testing phase. 

As per the WHO draft, from a total of 70 candidate vaccines in the race, three leading vaccines which are in the human testing phase are from CanSino Biological Inc and the Beijing Institute of Biotechnology; Inovio Pharmaceuticals Inc; and Moderna Inc along with the National Institute of Allergy and Infectious Diseases (NIAID) in the US.

What probably separates ChAdOx1 - known as recombinant viral vector vaccine - from the rest is the time it promises to take in order to deliver mass quantities


Trending